Letter from the Remuneration Committee Chair
Dearest Shareholders, As the incoming Chair of the Company, in short letters...
Read More
CLINUVEL Chair to Retire Following FDA Approval
CLINUVEL PHARMACEUTICALS LTD today announced that Mr Stan McLiesh will retire from...
Read More
Appendix 4G and Corporate Governance Statement
CLINUVEL PHARMACEUTICALS Corporate Governance Statement has been updated and is available...
Read More
Annual Report to shareholders
CLINUVEL’s Annual Report for the year ended 30 June 2019. Download...
Read More
Notice of Annual General Meeting/Proxy Form
This Explanatory Memorandum has been prepared for the Shareholders of the...
Read More
Audio Transcript Investor Teleconference
An audio transcript of the investor teleconference held yesterday can be...
Read More
FDA Grants Marketing Approval For SCENESSE
It is a privilege for CLINUVEL PHARMACEUTICALS LTD to announce the...
Read More
Trading Halt
The securities of Clinuvel Pharmaceuticals Limited (CUV) will be placed in...
Read More
CLINUVEL Renews Employment Agreement With CEO
CLINUVEL PHARMACEUTICALS LTD today announced that it has renewed the Employment...
Read More
FDA Clarifies SCENESSE® PDUFA Date
CLINUVEL PHARMACEUTICALS LTD today announced that the US Food and Drug...
Read More
CLINUVEL Confirms AGM Date
CLINUVEL PHARMACEUTICALS LTD today announced it will hold its 2019 Annual...
Read More
CLINUVEL Appoints New Director
CLINUVEL PHARMACEUTICALS LTD today announced the appointment of Susan (Sue) Smith...
Read More